10-12 July 2018
Boston, US

 

Speakers

Expand/Collapse

Rob Scott
CMO & VP, Global Development
Abbvie

Dr Rob Scott is Zimbabwean born and studied medicine at the University of Cape Town. He began his industry career with J&J in South Africa. In 1992 he joined Pfizer and became the Global Therapeutic Head for CV and Metabolic, responsible for what was then the world’s largest pharmaceutical product and the largest cardiovascular product – Lipitor and Norvasc. In 2002, he became the Chief Medical Officer and R&D Head at AtheroGenics, an emerging Pharma company in Atlanta Georgia. While at AtheroGenics, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech company. In 2008, he became the CMO and Head of Development of Cerenis Therapeutics in Toulouse, France. In 2010, he joined Amgen and ran a variety of therapeutic areas including Cardiovascular, Metabolic, Neuroscience, Bone, Nephrology and Inflammation Development. He was responsible for accelerating the development of Repatha which was the first PCSK9 inhibitor to be submitted in Europe and the USA. He also created and implemented a Center of Excellence focused on using predictive analytics for designing and implementing clinical trials. Since 2016, Dr Scott has been the Chief Medical Officer and Head of Development at Abbvie, managing a global organization of close to 3,000 people. Dr Scott was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and an occasional member on the Endocrine and Metabolic Advisory Committee. He sits on the Board of Transcelerate and the PhRMA Biomedical Advisory Committee. During his career, he has been involved with almost every therapeutic area and mode of drug delivery as well as both small molecules and biologics.  He developed the first drug combination to simultaneously treat two different disease states - Caduet.

Day One

Wednesday, July 11th, 2018

09.15 | Keynote: Accelerating & Transforming Clinical Development with mHealth Technology

08.30 | Opening Keynote Panel Discussion: Innovating the Conduct of Clinical Studies & Accelerating the Delivery of New Therapies to Patients with Mobile-Enabled Clinical Trials

Magdalena Schoeneich
Head, Takeda Digital Accelerator, R&D
Takeda

A “dots connector.” The one that doesn’t mind letting their inner child out and sometimes forgets to bring it back in. A prism seeker - I see what others see, but I also turn things backward, upside down, and inside out to see what others do not. A problem solver. Giver. Human I have a passion for imagining the future and turning it into the present. I spent time, looking at technologies of tomorrow and seeing how can they impact our work today. Then, I try to make it happen. I do not always succeed, but I enjoy trying and learning. I believe in concept of utilizing human-computer-networks to collect and spread the ideas (or as would you hear at TED the “ideas worth spreading”) in crowdsourcing (enabling us to take those ideas and turn them into reality) and in human desire (and ability) to remain humble, to learn and to use those inventions to the best of our abilities.

Day One

Wednesday, July 11th, 2018

08.30 | Opening Keynote Panel Discussion: Innovating the Conduct of Clinical Studies & Accelerating the Delivery of New Therapies to Patients with Mobile-Enabled Clinical Trials

Day Two

Thursday, 12th July, 2018

09.00 | Keynote: Connecting the Dots to mHealth & Digital Innovation Implementation in Clinical Trials

Gergely Vertes
Solution Accelerator Lead
UCB

Gergely holds an economics background and earned his MBA from Vlerick Business School and is currently drives some of UCB’s ‘wearables in epilepsy’ projects as a solution accelerator lead. His main focus is building a bridge between the technical/scientific and business requirements.  His previous work focused on specific populations living with epilepsy (pediatrics, women of childbearing potential) and included managing pediatric indication extension efforts at UCB globally.

Day Two

Thursday, 12th July, 2018

15.10 | Panel Discussion: What’s next?

Joseph Kim
Senior Advisor - Clinical Innovation
Eli Lilly

Joseph Kim serves as a Senior Advisor in Patient Experience and Design Innovation at Lilly, focusing on developing and implementing innovative patient engagement solutions. He has spent nearly 20 years in the Pharma industry utilizing a unique approach that integrates his experiences working for Sponsors such as Shire and Merck, CROs, and technology vendors. He has a robust combination of experience that includes early and late phase clinical research, and a well known history of innovation in the clinical research industry, recognized as one of “Top 100 individuals on the 2015 MedicineMakers Power List, and “20 Innovators Changing the Face of the Clinical Trials Industry” by CenterWatch in 2013.  He holds a BS in Molecular Biology from Lehigh University and an MBA from Villanova. He can be reached at kim_joseph_p@lilly.com and on Twitter: @JoPeKim

Day Two

Thursday, 12th July, 2018

09.30 | Difficulty of 10: Lessons Learned from a Mixed Location, Connected Care Trial

Michelle Crouthamel
Digital Platform Leader
GlaxoSmithKline

Michelle Crouthamel is the digital platform leader of the Clinical Innovation Unit at GlaxoSmithKline (GSK). Michelle’s passion for driving patient-centricity in the pharmaceutical industry led her to become an ‘Intrapreneur’ at GSK, and the founding member of the Clinical Innovation Unit, which focuses on harnessing digital technologies and platforms to improve patient engagement and clinical trials. Michelle is currently leading the strategy and pilot programs of e-Recruitment and m-Health platforms, and is involved in the industry-wide consortium, TransCelerate, eSource work stream. Over past 15 years, Michelle led many successful programs in discovery and development at both Merck and GSK, is an inventor who holds multiple patents, and has published extensively in the areas of Neuroscience, Oncology, and Digital Health. Michelle has a Master’s degree from the Institute of Neuroscience, and a Bachelor’s degree in Nursing from the National Yang-Ming University, Taiwan. She is currently pursuing a doctoral degree at Fox Business School, Temple University with a research focus on the Patient-Centricity in the pharmaceutical industry.

Day One

Wednesday, July 11th, 2018

08.30 | Opening Keynote Panel Discussion: Innovating the Conduct of Clinical Studies & Accelerating the Delivery of New Therapies to Patients with Mobile-Enabled Clinical Trials

Amir Lahav
Digital Innovation Lead, Rare Disease
Pfizer

Amir is neuroscientist working at the intersection of clinical innovation, digital biomarkers, and patient technology. His work is focused on evaluating the impact of real-world data using wearable devices and sensor intelligence with broad-range of clinical applications involving remote activity tracking, physiological monitoring, and digital voice capturing in the neuromuscular space. Amir strives to transform the way we do clinical trials while understanding barriers to change, especially as it related to the integration of cloud-based digital platforms and the development of incentivize gamification techniques to leverage protocol adherence and retention. With the regulatory landscape evolving, Amir is developing new strategies and scientific rationale for validating novel digital endpoints that are meaningful for patients, families, and regulators. He is also exploring advanced analytics tool where machine learning and artificial intelligence can help connect data points to provide clinical insights otherwise overlooked in the clinic. Amir served as a scientific medical advisor for several companies and have contributed to the development and design of a number of inventions in the pediatric medical device space and digital rehab technology. Prior to the pharma industry, Amir served as a professor of pediatrics and neurology faculty at Harvard Medical School and Harvard School of Public Health.

Day One

Wednesday, July 11th, 2018

15.45 | Panel Discussion: Debating Developments in New Clinical Digital Endpoints

Ching Tian
General Manager, Digital Accelerator
Novartis

Ching is a General Manager of Digital Accelerator in Novartis Global Drug Development currently leading the decentralized clinical trial effort. Ching has over twenty years experience from biotech/pharma and CRO. She was most recently at PPD as Vice President of Early Clinical Development Services leading the cross-functional CRO service organization. Prior to this role, she led the technology modernization effort in global pharmacovigilance organization at PPD. She also spent thirteen years at biotech company MedImmune in positions with increasing responsibilities and was lastly Senior Director of Clinical Informatics overseeing Data Management, Statistical Programming, Clinical System Operations and Strategy.

Day One

Wednesday, July 11th, 2018

15.15 | Novartis Journey on Decentralized Clinical Trials

Kyle Holen
Head, Development Design Center
AbbVie

Trained as a medical oncologist at Columbia University and Memorial Sloan-Kettering Cancer Center, Kyle began his career treating patients with GI tumors at the University of Wisconsin. There, his research interests included early phase trials and novel therapies for GI and neuroendocrine tumors. His educational responsibilities included leading the UW medical oncology fellowship program. He left academia to pursue drug development at AbbVie in 2009 and has since had roles as medical director, senior medical director, senior project lead, and executive medical director. He is currently the head of the Development Design Center, a center that assists clinical teams with their programs and trials using big data/predictive analytics and innovative strategies.

Day One

Wednesday, July 11th, 2018

15.45 | Panel Discussion: Debating Developments in New Clinical Digital Endpoints

Stacey Boyer
VP, Clinical Research Operations
Cavion

Dr. Boyer is an experienced biotech and pharma R&D executive leading translational through late-stage clinical development in multiple CNS indications. Presently, Dr. Boyer is the Vice President of Clinical Research Operations at Cavion, Inc., a clinical-stage pharmaceutical company developing first-in-class therapies which modulate overactive T-type channels. Prior to, Dr. Boyer concentrated in strategy and operations at Takeda Pharmaceuticals, Biogen, and Pfizer. Dr. Boyer holds Clinical Research Professional and National Institutes of Health certifications and actively contributes to the CNS field via numerous peer-reviewed publications.

Day Two

Thursday, 12th July, 2018

13.10 | Scaling to Small - Implementing mHealth in Emerging Biopharma Clinical Trials

Georgia Mitsi
Senior Director - Search Evaluation & Digital Healthcare
Sunovion Pharmaceuticals

Georgia Mitsi, PhD, is Senior Director, Search Evaluation & Digital Health Care Initiatives at Sunovion, where she oversees initiatives that focus on integrating digital health technologies into Sunovion’s solutions to contribute towards the goals to significantly to empower patients to better manage their symptoms and improve quality of life for those who are living with chronic medical conditions.  She also contributes to Sunovion’s support of public-private partnerships designed to accelerate digital health care solutions. Dr. Mitsi is a hands-on digital innovator with expertise in health outcomes and health economics research and experience in pharmaceutical and health care industry consulting. She is an active blogger on a variety of digital health care topics, and has authored numerous scientific publications and two novels.  Dr. Mitsi has been a long-time supporter and mentor to digital health start-up companies. She holds an MBA in international business from the University of Miami School of Business Administration, and a PhD in Pharmacoepidemiology and MSc in Applied Medical Sciences from the University of Patras.

Day One

Wednesday, July 11th, 2018

16.30 | Chair’s Closing Remarks

Day Two

Thursday, 12th July, 2018

15.55 | Chair’s Closing Remarks

10.55 | Inspiring Digital Transformation in Pharma: Use-Cases

08.45 | Chair’s Opening Remarks

Stephen Amato
Project Manager - Digital Innovation
Pfizer

Dr. Stephen Amato is a manager within Pfizer Global Product Development and is currently working to drive clinical innovation by leveraging mobile technologies to make clinical trial participation more engaging, informative and less burdensome, while simultaneously increasing the quality of data obtained. Prior to joining the mClinical team, Dr. Amato managed the BlueSky project, a collaboration between Pfizer and IBM tasked with using wearable sensor modalities to develop a remote monitoring platform intended to quantify the motor signs of people with Parkinson’s disease. Dr. Amato received his Ph.D. in Biology from Boston University and held a postdoctoral fellowship performing novel drug target identification and validation at Pfizer.

Lauren Bataille
Senior Associate Director - Research Partnerships
The Michael J. Fox Foundation for Parkinson's Research

Lauren Bataille joined The Michael J. Fox Foundation in August 2015. In her role, she leads Fox Insight, the Foundation’s landmark online clinical study aiming to enroll 125,000 participants over the next five years. Prior to joining MJFF, Lauren was the Director of Programs at Basic Health International where she managed pilot programs and clinical trials focused on cervical cancer prevention in low-resource settings. Lauren also worked at the consulting firm Global Health Strategies where she created advocacy and communications campaigns for health-focused foundations and nonprofits.

Spyros Papapetropoulos
Executive VP, R&D & Chief Medical Officer
Cavion

Spyros is a recognized researcher, an experienced biopharmaceutical executive, a digital health pioneer and a change agent. Prior joining Cavion as Head of Research and Development and CMO, he held positions of increasing responsibility at Biogen’s Experimental Neurology Unit, Allergan’s Global Medical Affairs, Pfizer’s Neuroscience Research Unit and TEVA’s Specialty Research and Development. He has filed multiple INDs and has overseen a wide spectrum of pharmaceutical development programs leading to successful regulatory filings and new product launches worldwide. For the past 10 years he has led multiple efforts in digital health developing standards and novel technology-based tools and solutions. Spyros is a board-certified Neurologist trained at the University of Patras and Queen’s Square/UCL, London, UK and holds appointments as Consultant with Massachusetts General Hospital and Voluntary Professor of Neurology with the University of Miami, Miller School of Medicine. He has authored more than 160 peer-reviewed publications, several book chapters, presented and chaired meetings since 1998. Spyros is a member of various US government and non-profit committees on healthcare and biomedical research innovation.

Day One

Wednesday, July 11th, 2018

08.15 | Chair’s Opening Remarks

Dmitri Talantov
Senior Director, Medical Affairs, Janssen Clinical Innovation
Janssen Pharmaceuticals

Dmitri Talantov, M.D., is a medical leader with Janssen Clinical Innovation (JCI), a team within Janssen R&D whose mission is to improve efficiency and drive innovation for clinical trials. In this role, Dr. Talantov leads development of new clinical trial models, including direct-to-patient and hybrid trials, integration of the digital technology in clinical trials. Prior to joining JCI, Dr. Talantov served as a medical director with Janssen Healthcare Innovation, where he led evidence-generation efforts across its portfolio and worked to develop and implement integrated care solutions in commercial settings. Previously, he was also responsible for translational medicine components of early clinical development programs in immunology and in cardiovascular and metabolic therapeutic areas with Janssen R&D. He had also led multiple projects around molecular cancer diagnostics with the Medical Diagnostic & Devices sector of Johnson & Johnson. He was formerly an internal medicine physician for 10 years in Kazan, Russia. Dr. Talantov earned his medical degree at Kazan State Medical University in Russia and has received notable awards over the course of his career.

Jeremy Wyatt 
CTO & Senior VP - Product Development
ActiGraph

Jeremy Wyatt is the Chief Technology Officer and Sr. Vice President of Product Development at ActiGraph, a global provider of physical activity and sleep monitoring solutions for the pharmaceutical and academic industries.  After graduating with his electrical engineering degree from the University of Florida, Jeremy spent six years as an embedded systems developer, redesigning hardware systems for military aircraft.  He joined the ActiGraph team as a founding member in 2004 and worked with the team to develop one of the world's first FDA class II cleared activity and sleep monitors.  Before taking his role as an executive, Jeremy earned his MBA from the University of West Florida in 2010. Today, Jeremy and the team continue to serve the global academic and pharmaceutical clinical trial market with a presence in 85 countries.  Their flagship software platform, CentrePoint, provides clinical trial teams with a secure, centralized platform for deploying and capturing actigraphy data from thousands of patients across multiple countries by leveraging cloud infrastructure and cellular technology.

Helina Kassahun
Clinical Research Medical Director, Cardiovascular & Metabolic Therapeutic Area
Amgen

Helina is a Clinical Research Medical Director in Cardiovascular & Metabolic Therapeutic Area at Amgen.

Day One

Wednesday, July 11th, 2018

15.45 | Panel Discussion: Debating Developments in New Clinical Digital Endpoints

Christina Silcox
Research Associate
Duke-Margolis Center for Health Policy

Dr. Christina Silcox, PhD, MS is a Research Associate at the Duke-Margolis Center for Health Policy, working on policy solutions to advance innovation and improve regulation and evaluation of medical products, with a concentration on medical devices and digital health. Recent projects include quality characterization of real-world data, the use of patient-generated health data collected through mHealth, and value-based payments for medical products. Before she joined Duke-Margolis, Dr. Silcox was a senior fellow at the National Center for Health Research. She earned a M.S. from the Massachusetts Institute of Technology (MIT) in Electrical Engineering and a Ph.D. in Medical Engineering and Medical Physics from the Harvard-MIT Division of Health Sciences and Technology (HST).

Claudio Soares
Professor & Head, Department of Psychiatry
Queen’s University School of Medicine

Dr. Soares is a Professor and Head of the Department of Psychiatry at Queen’s University School of Medicine in Kingston, Ontario (Canada) and Executive Lead for Strategy, New Partnerships for the Canadian Biomarker Integration Network in Depression (CAN-BIND); he also leads CAN-BIND’s Research Platform for M-Health, Innovation and Technology.  Dr. Soares is a trained psychiatrist from the University of Sao Paulo, Brazil, where he earned his medical degree and completed his Ph.D. work on estrogen effects for the management of depression in midlife women. He further pursued a postdoctoral fellowship in Reproductive Psychiatry at the Massachusetts General Hospital, Harvard Medical School, where he later served as an Assistant Professor of Psychiatry and Director for Research for the Perinatal Psychiatry Program. Dr. Soares relocated to Canada in 2004, recruited by McMaster University. During his tenure at McMaster he led the Women’s Health Program and the Mood and Anxiety Disorders Division. Before joining Queen’s School of Medicine in 2016, Dr. Soares earned MBA degrees from Queen’s/Smith School of Business and Cornell University School of Management. Dr. Soares’ research interests include effective treatments for mood and anxiety disorders across the female life cycle, with particular emphasis on midlife women and the menopausal transition. Most recently, his research has focused on the use of mobile health technologies (M-Health) and the concept of digital phenotyping for a better understanding of sustained wellness, resilience and relapse in depression. He is a sought-after educator with more than 170 presentations at national and international meetings. He has written extensively, with more than 130 publications including articles in the Archives of General Psychiatry (JAMA Psychiatry), Menopause, Obstetrics and Gynecology, Journal of Clinical Psychiatry, American Journal of Psychiatry, to name a few. He is also a recipient of numerous grants and awards, including CIHR, ORF grants and 3 NARSAD Awards from the Brain and Behavior Research Foundation.

John Slattery
Director of Research & Innovation
Aces Health Inc.

John has 10+ years clinical research experience. He is CCRP and CCRA certified, and an expert in microbiome-gut-brain axis with over 30+ highly cited peer-reviewed publications focused primarily on Autism Spectrum Disorders.

Day Two

Thursday, 12th July, 2018

10.00 | How a Medical Internet of Things (mIoT) Integration & ePRO Saved Time, Resources & a Full Clinical Hold: A Case Study on mHealth + mIoT for a Landmark Autism Therapeutic Trial

Todd Grinnell
Senior Director, Medical Affairs, Neuro & Pain
Sunovion Pharmaceuticals

Todd Grinnell is Senior Director, Medical Affairs, Neuro and Pain at Sunovion, where he is the Medical Affairs lead for the epilepsy products portfolio.  In this role, Mr. Grinnell is actively involved in exploration of digital health technologies in post-marketing clinical research, including the use of wearable device technology to assess objective clinical endpoints and the extent to which novel physiological data may provide complementary evidence of both objective and subjective responses to therapeutic intervention.  Mr. Grinnell is keenly interested in the current and potential future role of various digital health technologies in providing a more comprehensive assessment of the role of Sunovion’s medications in contributing to better overall management of chronic medical conditions in the therapeutic areas of neurology and psychiatry.  He also contributes to the evaluation of potential new products and sourcing of novel technologies to enhance the development of those products. Todd has worked in the pharmaceutical industry for over 20 years in rolls as diverse as Discovery Research and Translational Medicine as well as Clinical Development and Medical Affairs. He received an AB in biochemistry from Harvard University with additional graduate work in molecular biology and neuroscience.

Day Two

Thursday, 12th July, 2018

10.55 | Inspiring Digital Transformation in Pharma: Use-Cases

Christina VanderPluym
Medical Director, Ventricular Assist Device Program & Medical Director, Cardiac Antithrombosis Management & Monitoring Program
Boston Children’s Hospital

Christina has been immersed in the field of pediatric cardiology since the age of 17 years, when she first began clinical research at the University of Alberta Stollery Children’s Hospital in heart transplantation. Her medical and fellowship training in Canada allowed unique insight to the field of mechanical circulatory support and anticoagulation. Christina completed further subspecialty training in the pediatric heart failure at Boston Children’s Hospital and became the Medical Director of the Ventricular Assist Device program and the Cardiac Antithrombosis Program in 2012.

Les Jordan
VP & Chief Product Evangelist (Target Health) / Project Team Member
Clinical Trials Transformation Initiative (CTTI)

As Vice President and Chief Product Evangelist for Target Health, Les Jordan is responsible for the software side of the Target Health business, providing overall product vision, technical direction to software development teams, along with overseeing sales and marketing. Prior to joining Target Health, Les spent almost 10 years as the CTO for Microsoft’s Life Sciences Industry Unit, where he was responsible for providing Life Science industry guidance to customers, partners and product teams, while serving as Microsoft’s representative to industry standards groups including CDISC, IHE and HL7. He also spent two years with Quintiles, responsible for sales and marketing for their IT Consulting Practice, five years with Webridge (now part of Huron Consulting) where he was responsible for launching their now market-leading suite of products into clinical trials and research compliance automation, and a year with Bad Rabbit Consulting where he served as Vice President of Everything, running a small consulting company focused on research compliance in universities and academic medical centers. Les is a noted expert and speaker on the topic of using technology to change the Health and Life Sciences industry, particularly around using patient engagement technologies to streamline how clinical trials are run and how drugs are brought to market.

Day Two

Thursday, 12th July, 2018

13.40 | Patient Perspectives on Mobile Technology in Clinical Trials – Overviewing Outcomes from the CTTI’s Mobile Clinical Trials (MCT) Program

Raj Pallapothu
mHealth & Internet of Things Advanced Specialist
Bayer

A ‘born Global’ Health Care Specialist & Entrepreneur with close to 2 decades of experience in Strategies & Partnerships, Technologies, Product Management and Supply Chain Management. Through my far-flung connectivity, I have the pleasure of working with tens of Digital Health Enterprises that are looking to change the world, creating patient value from Innovation & Digitized Pharma Therapeutics in the form of Smart Devices & Internet of Things [IoT] Solutions, Artificial Intelligence & Virtual Clinical practices adaptation. Firmly believe that future of health care won’t just be defined by the innovations we set out to create; it will be equally shaped by how we respond to – and anticipate – the challenges and consequences of each advancement.

Day Two

Thursday, 12th July, 2018

15.10 | Panel Discussion: What’s next?

14.40 | Driving Innovation in Clinical Trials by Open Data Connectivity Platforms Supporting Multiple Data Sources

Devon Coleman
Program Coordinator, Autism/Asperger’s Research Program
Arizona State University

Devon Coleman has worked in the ASU Autism/Asperger’s Research Program as a Program Coordinator for two and a half years. Devon is a certified clinical research coordinator that runs the day-to-day operations of a variety of studies for ASU's Autism research group, currently Devon is focusing on a double-blind placebo-controlled trial, “Microbiota Transfer Therapy for Adults with Autism Spectrum Disorder (ASD) who have Gastrointestinal Disorders,” which is what lead Devon to start working with Aces Health.

Day Two

Thursday, 12th July, 2018

10.00 | How a Medical Internet of Things (mIoT) Integration & ePRO Saved Time, Resources & a Full Clinical Hold: A Case Study on mHealth + mIoT for a Landmark Autism Therapeutic Trial

Larsson Omberg
VP, Systems Biology
Sage Bionetworks

Dr. Omberg is the VP Systems Biology at Sage Bionetworks overseeing a research agenda that focuses on two areas – using remote sensors and mobile phones to measure disease; and collaborative genomic research. Currently his group focuses heavily on open and team based science to get a large number of external partners to collaborate on data intensive problems.  This includes establishing norms and methods for measuring disease phenotypes using remote sensors and developing analytical approaches for turning raw signals from sensors into digital biomarkers.  Dr. Omberg and the Systems Biology group have been involved in over two dozen mobile health studies ranging from Chronic Anemia to Parkinson's Disease.  As a graduate student and postdoctoral researcher at the University of Texas and Cornell University Dr. Omberg developed machine learning and statistical approaches for extracting genomic phenotypes and disease signals from system level biological data. After establishing a data science group at Sage Bionetworks his expertise was applied to data integration and integrative analysis for the TCGA Pancancer collaboration, The Progenitor Cell Biology Consortium as well as the international ICGC/TCGA Whole Genome Pan-Cancer Analysis among other projects.  Dr. Omberg received a Ph.D. in physics from the University of Texas at Austin.

Workshop B

July 10 2018

13.00 | MHEALTH FROM THE TRENCHES: LESSONS IN PARTICIPANT ENGAGEMENT & ANALYTICAL APPROACHES FOR DEVELOPING INSIGHTS FROM DATA COLLECTED IN MOBILE HEALTH STUDIES

Woody MacDuffie
Principal User Experience Designer
Sage Bionetworks

Woody MacDuffie is a Principal Interaction Designer for Sage. Previously, Woody worked as a lead Interaction Designer at several early stage healthcare startups (98point6 and Practice Fusion) and helped designed several award winning products at UPMC’s Technology Development Center in Pittsburgh PA. He has a BS in Mechanical Engineering and Mathematics from Villanova University, MS in Mechanical Engineering from University of Pennsylvania and a MS in Industrial Design of University of the Arts.

Workshop B

July 10 2018

13.00 | MHEALTH FROM THE TRENCHES: LESSONS IN PARTICIPANT ENGAGEMENT & ANALYTICAL APPROACHES FOR DEVELOPING INSIGHTS FROM DATA COLLECTED IN MOBILE HEALTH STUDIES

Abhishek Pratap
Principal Research Scientist, Digital Health
Sage Bionetworks

Abhishek Pratap(Abhi) is a Principal Research Scientist at Sage Bionetworks and a researcher at University of Washington(UW), Seattle. His research focuses on designing affective mobile apps, and analytical workflows that will ultimately empower people in assessing their health symptoms and share its management with their care provider.  Abhi is involved in several mHealth projects for assessing  Depression,  Suicide risk factors, Parkinson's and Multiple Sclerosis diseases.  As part of the AllofUS program, he is co-leading the development of a Mood assessment app that will be deployed to a cohort of million  AllofUS volunteers. Before Sage, Abhi has worked in a various biomedical labs analyzing terabytes of high-throughput biomedical data. He has an MS in Engineering Management (CS) from University of Maryland, Baltimore County and a Graduate certificate in Bioinformatics from Stanford University.

Workshop B

July 10 2018

13.00 | MHEALTH FROM THE TRENCHES: LESSONS IN PARTICIPANT ENGAGEMENT & ANALYTICAL APPROACHES FOR DEVELOPING INSIGHTS FROM DATA COLLECTED IN MOBILE HEALTH STUDIES

João Bocas
Wearables Expert & Digital Health Influencer

João Bocas is a Wearables Expert, Top 100 Global Digital Health Influencer & Keynote Speaker. His passion lies in helping others, sharing experiences, transferring knowledge, working collaboratively and passing on the latest innovation trends from the digital health world. As a thought leader in wearables, digital health, IoT and big data in healthcare, João explores the intersection of technology in modelling business models and shaping consumer behaviour. Also he analyses the impact of disruptive innovations and shares future trends in the marketplace. He possesses more than 25 years of hands-on experience in Professional Sport and Corporate environments working with senior management, Boards and executive teams. He has worked across Healthcare, Financial Services, Media, Sporting, Third and Public Sector organisations.

Workshop A

July 10 2018

09.00 | EMERGING WEARABLE TECHNOLOGIES - TRUE POTENTIAL IN CLINICAL TRIALS